目的：通过体内和体外实验，验证雷公藤内酯醇是否具有预防同种异体移植术后急性排异反应的作用。方法：以环孢霉素Ａ（ＣｓＡ）为阳性对照，采用同种异体的皮肤移植和肾移植。结果：雷公藤内酯醇能够①明显延长同种异体移植的皮肤和肾的存活时间，雷公藤内酯醇剂量为２００μｇ／（ｋｇ·ｄ）时，二者的平均存活时间为１７２和２９１ｄ（对照组分别为９８和９２，Ｐ＜００１）；②联合使用亚有效剂量的雷公藤内酯醇与ＣｓＡ时，能够明显地延长同种异体移植的皮肤和肾脏的存活时间；③移植肾病理检查发现，雷公藤内酯醇治疗后，移植肾组织中病理损伤程度明显轻于未治疗组。结论：本研究表明，雷公藤内酯醇具有明显地抗同种异体急性排异反应的作用，并与ＣｓＡ有一定的协同作用 OBJECTIVE: To verify whether triptolide can prevent acute rejection after allogeneic transplantation by in vitro and in vivo experiments. METHODS: Cyclosporine A (CsA) was used as a positive control and allogeneic skin grafts and kidney transplants were used. Results: Triptolide could prolong the survival time of allograft skin and kidneys. When the triptolide dose was 200 μg / (kg · d), the average survival time was 172 and 29 respectively. 1d (control group, respectively, 9  8 and 9  2, P <0  01); ② combination of sub-effective doses of triptolide and CsA, can significantly extend the allograft skin and kidney survival Time; ③ renal grafts examination found that after triptolide treatment, the extent of pathological damage in renal transplant recipients was significantly lighter than the untreated group. Conclusion: This study shows that triptolide has obvious anti-allogeneic acute rejection reaction and has certain synergistic effect with CsA